Kristen Hsu, ARC’s Executive Director of Research, presented the most current updates for the clinical trial landscape, with a focus on AL amyloidosis. Kristen also discussed the direction future research.
The webinar concluded with a Q&A session.
Original Presentation Date:
April 15, 2025.
0:00 — Welcome
4:00 — Introduction
6:40 — What is a Clinical Trial?
7:52 — Clinical Trial Phases
13:00 — What makes a study a good fit for me?
16:09 — AL Amyloidosis Clinical Trial Overview
25:00 — AL Amyloidosis Trials Recruiting in 2025
25:54 — LINKER-AL2 (Relapsed/refractory AL amyloidosis)
30:04 — ENTENTAMIG (Relapsed/refractory AL amyloidosis)
33:17 — NEXICART-2 (Relapsed/refractory AL amyloidosis)
35:53 — AFFIRM-AL (Newly diagnosed AL amyloidosis)
38:58 — Upcoming Milestones for AL Therapies in 2025
43:00 — Future Development for AL Therapies
45:35 — Other Recruiting and Planned Clinical Trials
49:30 — How to Find Clinical Trials
52:48 — Q&A Session
53:37 — How do measurements of “free light chains” relate to disease progression?
56:10 — Which study is appropriate for patients who have already had an autologous stem cell transplant?
57:13 — Could CAR-T cell therapy eventually replace stem cell transplants?
58:08 — What is the timeline between a study concluding and treatments becoming available?
1:00:29 — What is the impact of current federal policy changes on amyloidosis research?
1:03:46 — Conclusion
Contact ARC:
Call +1 (617) 467-5170
Email ARC at support@arci.org
